VEGFA and neoplasm: In contrast, further serial clinical data showed discouraging results in that anti-VEGF therapy increases the metastatic potential and chemoresistance (Padera et al. 2008; Welch et al. 2010; Miles et al. 2011), indicating that tumor hypoxia recurs with anti-angiogenic therapy (Pennacchietti et al. 2003).